al., J. Neuroscience (2004) 24:1521-1529.
47) Obrietan, K. and K. Hoyt, J. Neuroscience (2004) 24:791-796.
48) Hantman, A.W. et al., J. Neuroscience (2004) 24:836-842.
49) Zappone, C.A. and R. Sloviter
Science, 244 (4905), 707-712 (1989).
6. Revillion, F. et al., ERBB2 Oncogene in Human
Breast Cancer and its Clinical Significance. Eur. J.
Cancer, 34, 791-808 (1998).
7. Ross, J.S., and Fletcher
80501336 791
D71P15HR1 15 kg 1 g 355 x 305 mm 80501303 759
D71P15HR1-M 15 kg 5 g 355 x 305 mm 80501310 817
D71P30QR1 30 kg 2 g 300 x 300 mm 80501332 733
D71P30QR1-M 30 kg 10 g 300 x 300 mm
COX-2 Inhibitor II 236012 {4-[(5-Difluoromethyl-3-phenyl)-4-isoxazolyl]benzenesulfonamide; SC-791}
A cell-permeable isoxazolyl-benzenesulfonamide compound that acts as a
potent and highly selective